Independent Non-Executive Chairman

Thomas J.R. O’Brien AM, B.Econ., B.Com. (Hons), FCA, FCPA, FAICD

Director and Chairman since April 2004, Mr O’Brien is also Chairman of the Audit Committee and the Remuneration Committee. Mr. O’Brien was Chief Executive Officer (Melbourne) for the international accounting firm of Ernst and Young for 12 years, and was also National Chairman of Ernst & Young Australia in 1995 and 1996.

Mr. O’Brien currently serves on a number of boards, including Allans Music Group Pty Ltd and Virtual Communities Limited. He is currently Chairman of Church Resources, CCI Investment Management Limited, HLT Limited and Domaines Tatiarra Limited. He was formerly Chairman of St Vincents and Mercy Private Hospital Limited and a member of the Board of Mercy Health and Aged Care.

Managing Director and Chief Executive Officer

Dennis Bastas B.E., MAICD

Appointed Managing Director and CEO on formation of the Company in December 2003, Dennis was the founding force behind the initial strategy and creation of the Company. He has extensive senior management experience in business development, retail services and supply chain management with companies including Coles Myer Limited, Mannesmann AG and Village Roadshow Limited.

Non-Executive Director

Warren J. Jenkins, B.Sc.

Director since February 2007, Mr Jenkins has over 30 years experience in the global pharmaceutical industry having held senior executive positions at Smith Kline and Eli Lilly before joining Serono, a global biotechnology leader with over 4,750 employees, to build its regional Asia-Pacific sales and marketing operations as Regional Vice President, Oceania and Japan. Most recently Mr. Jenkins held the position of Vice-President Sales and Marketing, Europe & International for Serono.

Non-Executive Director

Dr Roger Aston, B.Sc. (Hons), Phd.

Director since February 2008, Dr Aston brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the United Kingdom, Asia-Pacific and Australia. In conjunction with his new appointment, Roger continues to serve as an executive, non-executive director or chairman on a number of boards including Phase III drug development companies Clinuvel Limited and HalcyGen Pharmaceuticals Limited. Previously he founded and was CEO of pSiOncology Pty Limited, a joint venture based in Singapore between Singapore General Hospital, Biotech Research Ventures and pSiMedica Limited.

Company Secretary

Jo-Anne Dal Santo, B.Bus, ACIS

Ms Dal Santo was appointed Company Secretary on 17 May 2006. Prior to this position Ms Dal Santo held a variety of accounting and finance roles in private industry and is currently an associate of Chartered Secretaries Australia.